Inuyama Y, Fujii M, Tanaka J, Takaoka T, Hosoda H
Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1797-803.
From 1963 through 1986, we examined 91 patients with carcinoma of the oropharynx. Of these 91 patients, the primary treatment modality was chosen for 75 patients. The patients were divided into 2 groups according to the periods of treatment. In group I (1963-1973), 33% of the patients were applied combined radiotherapy and chemotherapy, and 28% chemotherapy followed by surgery as their initial treatment. In group II (1974-1986), 65% of the patients were applied combined radiotherapy and chemotherapy, and 21% a multimodal treatment consisting of radiotherapy combined with chemotherapy followed by composite resection. Five-year survival rate was 36% in group I and 51% in group II, which indicated a progress in the treatment of carcinoma of the oropharynx. The role of surgical treatment for carcinoma of the oropharynx was discussed. It appears that composite resection and reconstructive surgery produced a great benefit in the treatment of residual diseases after radiotherapy or recurrent diseases. Then our new treatment modality incorporating neo-adjuvant chemotherapy was presented. The literatures in terms of neo-adjuvant chemotherapy were reviewed.
从1963年到1986年，我们检查了91例口咽癌患者。在这91例患者中，为75例患者选择了主要治疗方式。根据治疗时期将患者分为两组。在第一组（1963 - 1973年），33%的患者采用放疗和化疗联合治疗，28%的患者最初采用化疗后手术治疗。在第二组（1974 - 1986年），65%的患者采用放疗和化疗联合治疗，21%的患者采用放疗联合化疗后进行复合切除的多模式治疗。第一组的五年生存率为36%，第二组为51%，这表明口咽癌的治疗取得了进展。讨论了手术治疗在口咽癌治疗中的作用。似乎复合切除和重建手术在放疗后残留疾病或复发性疾病的治疗中产生了很大益处。然后提出了我们包含新辅助化疗的新治疗模式。回顾了有关新辅助化疗的文献。
